(Q37261946)

19 August 2017

1 reference

title

What is the best approach for screen-detected low volume cancers?--The case for observation (English)

1 reference

19 August 2017

1

Laurence Klotz

1 reference

19 August 2017

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

26

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

495-499

1 reference

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

7 January 2021

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

20-year outcomes following conservative management of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Prostate cancer and the Will Rogers phenomenon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Carcinoma of the prostate: a 15-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

The risk of dying of prostate cancer in patients with clinically localized disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Deferred treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Deferred treatment in clinically localised prostatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Prognosis of localised prostatic cancer managed by "watch and wait" policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Expectant management of localized prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Natural history of localised prostatic cancer managed by conservative therapy alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Long-term survival in a Swedish population-based cohort of men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Active surveillance: towards a new paradigm in the management of early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Active surveillance: an individualized approach to early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Prostate biopsy: how many cores are enough?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Lead time associated with screening for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

PSA doubling time of prostate carcinoma managed with watchful observation alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Active surveillance for prostate cancer: for whom?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Radical prostatectomy versus watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Quality of life after radical prostatectomy or watchful waiting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

The role of watchful waiting in the management of localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.003

10.1016/J.UROLONC.2008.03.003

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference